Adipocytokines in renal transplant recipients Kristof Nagy1

Clinical Kidney Journal

Volumn 9, Issue 3, 2016, Pages 359-373

  Nagaraju, Shankar Prasad ^b   Rhee, Connie M ^c   Mathe, Zoltan ^a   Molnar, Miklos Z ^d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b KASTURBA MEDICAL COLLEGE   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adiponectin; Kidney transplantation; Leptin; Resistin; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TACROLIMUS;

CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNE STATUS; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; REVIEW;

EID: 84978998408     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv156     Document Type: Review

References (213)

1. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783
2. Agras PI, Baskin E, Saatci U et al. Relationship between leptin and bone mineral density in renal transplant recipients. Transplant Proc 2005; 37: 3106-3108
3. Agras PI, Saatci U, Baskin E et al. Hyperleptinemia and its relation with peripheral C34(+)CD7(+) stem cells in renal transplant recipients. Transpl Immunol 2006; 15: 241-245
4. Baczkowska T, Soin J, Soluch L et al. The role of leptin in body mass index increase in renal allograft recipients. Transplant Proc 2000; 32: 1331-1332
5. El Haggan W, Chauveau P, Barthe N et al. Serum leptin, body fat, and nutritional markers during the six months post-kidney transplantation. Metabolism 2004; 53: 614-619
6. Fonseca I, Oliveira JC, Santos J et al. Leptin and adiponectin during the first week after kidney transplantation: biomarkers of graft dysfunction? Metabolism 2015; 64: 202-207
7. Kagan A, Haran N, Leschinsky L et al. Serum concentrations of leptin in heart, liver and kidney transplant recipients. Isr Med Assoc J 2002; 4: 213-217
8. Kayacan SM, Yildiz A, Kazancioglu R et al. The changes in serum leptin, body fat mass and insulin resistance after renal transplantation. Clin Transplant 2003; 17: 63-68
9. Kokot F, Adamczak M,Wiecek A. Plasma leptin concentration in kidney transplant patients during the early post-transplant period. Nephrol Dial Transplant 1998; 13: 2276-2280
10. Kokot F, Adamczak M,Wiecedil et al. Plasma immunoreactive leptin and neuropeptide Y levels in kidney transplant patients. Am J Nephrol 1999; 19: 28-33
11. Kovesdy CP, Molnar MZ, Czira ME et al. Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5: 2297-2304
12. Landt M, Brennan DC, Parvin CA et al. Hyperleptinaemia of end-stage renal disease is corrected by renal transplantation. Nephrol Dial Transplant 1998; 13: 2271-2275
13. Lee MC, Lee CJ, Ho GJ et al. Hyperleptinemia positively correlated with metabolic syndrome in renal transplant recipients. Clin Transplant 2010; 24: E124-E1249
14. Lee MC, Chen YC, Ho GJ et al. Serum leptin levels positively correlate with peripheral arterial stiffness in kidney transplantation patients. Transplant Proc 2014; 46: 353-358
15. Malyszko J, Malyszko JS, Pawlak K et al. Correlations between leptin, body composition, bone mineral density, and bone metabolism in kidney transplant recipients. Transplant Proc 2005; 37: 2151-2153
16. Nicoletto BB, Souza GC, Goncalves LF et al. Leptin, insulin resistance, and metabolic changes 5 years after renal transplantation. J Ren Nutr 2012; 22: 440-449
17. Rafieian-Kopaei M, Nasri H. Serum leptin in renal transplant patients. JRIP 2013; 2: 55-57
18. Souza GC, Costa CA, Goncalves LF et al. Leptin serum levels in the first year post-renal transplantation. Transplant Proc 2007; 39: 439-440
19. Adamczak M, Szotowska M, Chudek J et al. Plasma adiponectin concentration in patients after successful kidney transplantation-a single-center, observational study. Clin Nephrol 2007; 67: 381-390
20. Adamczak M, Blach A, Kolonko A et al. Plasma adiponectin concentration and left ventricular hypertrophy in kidney transplant patients. Clin Transplant 2011; 25: 561-568
21. Alam A, Molnar MZ, Czira ME et al. Serum adiponectin levels and mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8: 460-467
22. Bayes B, Granada ML, Pastor MC et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007; 7: 416-422
23. Bayes B, Granada ML, Lauzurica R et al. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplant Proc 2005; 37: 3808-3812
24. Canas L, Bayes B, Granada ML et al. Is adiponectin a marker of preclinical atherosclerosis in kidney transplantation? Clin Transplant 2012; 26: 259-266
25. Chitalia N, Raja RB, Bhandara T et al. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol 2010; 23: 77-84
26. Chudek J, Adamczak M, Karkoszka H et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186-2189
27. Chudek J, Szotowska M, Karkoszka H et al. Genotypes of renin-angiotensin system and plasma adiponectin concentration in kidney transplant patients. Ann Transplant 2013; 18: 593-603
28. Ho GJ, Lee MC, Lee CJ et al. Hypoadiponectinemia correlates with arterial stiffness in kidney transplantation patients. Clin Exp Nephrol 2015; 19: 534-541
29. Idorn T, Hornum M, Bjerre M et al. Plasma adiponectin before and after kidney transplantation. Transpl Int 2012; 25: 1194-1203
30. Kaisar MO, Armstrong K, Hawley C et al. Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrol 2009; 10: 29
31. Kang ES, Magkos F, Kim BS et al. Variants of the adiponectin and adiponectin receptor-1 genes and posttransplantation diabetes mellitus in renal allograft recipients. J Clin Endocrinol Metab 2012; 97: E129-E135
32. Kulshrestha S, Ojo AO, Luan FL. Metabolic syndrome, vitamin D deficiency and hypoadiponectinemia among nondiabetic patients early after kidney transplantation. Am J Nephrol 2013; 37: 399-404
33. Lee MC, Lee CJ, Chou KC et al. Hypoadiponectinemia correlates with metabolic syndrome in kidney transplantation patients. Transplant Proc 2011; 43: 2601-2605
34. Leibowitz A, Peleg E, Ben-David A et al. Normal adiponectin levels in kidney transplant patients with hypertension. Clin Transplant 2013; 27: 562-566
35. Malyszko J, Malyszko JS, Brzosko S et al. Markers of endothelial cell activation/injury: CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients. Am J Nephrol 2005; 25: 203-210
36. Nicoletto BB, Souza GC, Fonseca NK et al. Association between 276G/T adiponectin gene polymorphism and newonset diabetes after kidney transplantation. Transplantation 2013; 96: 1059-1064
37. Nishimura K, Kishikawa H, Kato T et al. Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in new-onset diabetes after renal transplantation: single-center cross-sectional analysis. Transpl Int 2009; 22: 694-701
38. Prasad GV, Vorobeichik L, NashMMet al. Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients. Clin Kidney J 2012; 5: 124-129
39. Roos M, Baumann M, Liu D et al. Low pre-transplant adiponectin multimers are associated with adverse allograft outcomes in kidney transplant recipients a 3-year prospective study. Regul Pept 2012; 178: 11-15
40. Sethna CB, Leonard MB, Gallagher PR et al. Serum adiponectin levels and ambulatory blood pressure monitoring in pediatric renal transplant recipients. Transplantation 2009; 88: 1030-1037
41. Shen YY, Charlesworth JA, Kelly JJ et al. The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007; 56: 1201-1208
42. Shu KH, Tsai IC, Ho HCet al. Serum adiponectin levels in renal transplant recipients with and without metabolic syndrome. Transplant Proc 2012; 44: 676-679
43. Taherimahmoudi M, Ahmadi H, Mehrsai A et al. Plasma adiponectin concentration and insulin resistance: role of successful kidney transplantation. Transplant Proc 2010; 42: 797-800
44. Teplan V, Schuck O, Stollova M et al. Obesity and adiponectin after kidney transplantation. Acta Physiol Hung 2007; 94: 149-157
45. Teplan V, Schuck O, Racek J et al. Asymmetric dimethylarginine and adiponectin after renal transplantation: role of obesity. J Ren Nutr 2008; 18: 154-157
46. Yilmaz MI, Saglam M, Caglar K et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005; 80: 1660-1666
47. Yu AR, Xin HW, Wu XC et al. Adiponectin gene polymorphisms are associated with posttransplantation diabetes mellitus in Chinese renal allograft recipients. Transplant Proc 2011; 43: 1607-1611
48. Axelsson J,Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244
49. Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a nontraditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med 2010; 21: 530-535
50. Carrero JJ, Witasp A, Stenvinkel P et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010; 25: 901-906
51. Eleftheriadis T, Pissas G, RemoundouMet al. Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin. Ren Fail 2013; 35: 1399-1403
52. Erten Y, Ebinc FA, Ebinc H et al. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2008; 30: 617-623
53. Kato A, Odamaki M, Ishida J et al. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 2009; 29: 31-35
54. Lu YC, Hsu CC, Yu TH et al. Association between visfatin levels and coronary artery disease in patients with chronic kidney disease. Iran J Kidney Dis 2013; 7: 446-452
55. Mahmood N, Junejo AM, Jamal Q et al. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes. J Pak Med Assoc 2010; 60: 922-926
56. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 2009; 41: 150-153
57. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial function in dialyzed patients. Nephrology 2010; 15: 190-196
58. Mu J, Feng B, Ye Z et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011; 24: 177-184
59. Yilmaz MI, Saglam M, Carrero JJ et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009; 23: 241-248
60. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965
61. Akagun T, Caliskan Y, Yazici H et al. Elevated resistin levels are associated with inflammation in hemodialysis patients with failed renal allografts. Int J Artif Organs 2014; 37: 358-363
62. ChungW, Jung ES, Shin D et al. Lowresistin level is associated with poor hospitalization-free survival in hemodialysis patients. J Korean Med Sci 2012; 27: 377-381
63. Dan S, Aditya P, Banerjee P et al. Effect of chronic kidney disease on serum resistin level. Niger J Clin Pract 2014; 17: 735-738
64. Filippidis G, Liakopoulos V, Mertens PR et al. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif 2005; 23: 421-428
65. Kawamura R, Doi Y, Osawa H et al. Circulating resistin is increased with decreasing renal function in a general Japanese population: the Hisayama Study. Nephrol Dial Transplant 2010; 25: 3236-3240
66. Kaynar K, Kural BV, Ulusoy S et al. Is there any interaction of resistin and adiponectin levels with protein-energy wasting among patients with chronic kidney disease. Hemodial Int 2014; 18: 153-162
67. Kielstein JT, Becker B, Graf S et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42: 62-66
68. Malyszko J, Malyszko JS, Pawlak K et al. Resistin, a newadipokine, is related to inflammation and renal function in kidney allograft recipients. Transplant Proc 2006; 38: 3434-3436
69. Marouga A, Dalamaga M, Kastania AN et al. Correlates of serum resistin in elderly, non-diabetic patients with chronic kidney disease. Clin Lab 2012; 59: 1121-1128
70. Oltean S, Pullerits R, Floden A et al. Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation. J Transl Med 2013; 11: 233
71. Spoto B, Mattace-Raso F, Sijbrands E et al. Resistin and allcause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrol Dial Transplant 2013; 28(Suppl 4): iv181-iv187
72. Attoub S, Noe V, Pirola L et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho-, and Rac-dependent signaling pathways. FASEB J 2000; 14: 2329-2338
73. Hama H, Saito A, Takeda T et al. Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 2004; 145: 3935-3940
74. Yang R, Barouch LA. Leptin signaling and obesity cardiovascular consequences. Circ Res 2007; 101: 545-559
75. Bjørbæk C, Buchholz RM, Davis SM et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001; 276: 4747-4755
76. Simonds SE, Cowley MA, Enriori PJ. Leptin increasing sympathetic nerve outflow in obesity: a cure for obesity or a potential contributor to metabolic syndrome? Adipocyte 2012; 1: 177-181
77. Dhillon SS, Belsham DD. Leptin differentially regulates NPY secretion in hypothalamic cell lines through distinct intracellular signal transduction pathways. Regul Pept 2011; 167: 192-200
78. Shen YY,Hughes JT, Charlesworth JA et al. Adiponectin is present in the urine in its native conformation, and specifically reduces the secretion of MCP-1 by proximal tubular cells. Nephrology (Carlton) 2008; 13: 405-410
79. Liu M, Liu F. Regulation of adiponectin multimerization, signaling and function. Best Pract Res Clin Endocrinol Metab 2014; 28: 25-31
80. Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012; 6: 120-124
81. Romacho T, Villalobos LA, Cercas E et al. Visfatin as a novel mediator released by inflamed human endothelial cells. PLoS One 2013; 8: e78283
82. Aruna B, Ghosh S, Singh AK et al. Human recombinant resistin protein displays a tendency to aggregate by forming intermolecular disulfide linkages. Biochemistry 2003; 42: 10554-10559
83. Patel SD, Rajala MW, Rossetti L et al. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004; 304: 1154-1158
84. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci (Lond) 2005; 109: 243-256
85. Reilly MP, Lehrke M, Wolfe ML et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939
86. Fadda SM, Gamal SM, Elsaid NY et al. Resistin in inflammatory and degenerative rheumatologic diseases. Relationship between resistin and rheumatoid arthritis disease progression. Z Rheumatol 2013; 72: 594-600
87. Karmiris K, Koutroubakis IE, Xidakis C et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 100-105
88. Fujie S, Sato K, Miyamoto-Mikami E et al. Reduction of arterial stiffness by exercise training is associated with increasing plasma apelin level in middle-aged and older adults. PLoS One 2014; 9: e93545
89. Malyszko J, Malyszko JS, Pawlak K et al. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc 2008; 40: 3466-3469
90. Yamamoto T, Qureshi AR, Anderstam B et al. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant 2010; 25: 4017-4023
91. Ruster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant 2013; 28(Suppl 4): iv8-iv14
92. Miyamoto S, Sharma K. Adipokines protecting CKD. Nephrol Dial Transplant 2013; 28(Suppl 4): iv15-iv22
93. Molnar MZ, Czira ME, Rudas A et al. Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 58: 101-108
94. Molnar MZ, Tabak AG, Alam A et al. Serum erythropoietin level and mortality in kidney transplant recipients. Clin J Am Soc Nephrol 2011; 6: 2879-2886
95. Kovesdy CP, Mucsi I, Czira ME et al. Association of serum phosphorus level with anemia in kidney transplant recipients. Transplantation 2011; 91: 875-882
96. Molnar MZ, Czira ME, Rudas A et al. Association between the malnutrition-inflammation score and post-transplant anaemia. Nephrol Dial Transplant 2011; 26: 2000-2006
97. Kovesdy CP, Czira ME, Rudas A et al. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 2010; 10: 2644-2651
98. Molnar MZ, Keszei A, Czira ME et al. Evaluation of the malnutrition-inflammation score in kidney transplant recipients. Am J Kidney Dis 2010; 56: 102-111
99. Cumin F, Baum HP, Levens N. Leptin is cleared fromthe circulation primarily by the kidney. Int J Obes Relat Metab Disord 1996; 20: 1120-1126
100. Zou Z, Chung B, Nguyen T et al. Linking receptor-mediated endocytosis and cell signaling evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem 2004; 279: 34302-34310
101. Shah M, Baterina OY, Taupin V. ARH directs megalin to the endocytic recycling compartment to regulate its proteolysis and gene expression. J Cell Biol 2013; 202: 113-127
102. Meyer C, Robson D, Rackovsky N. Role of the kidney in human leptin metabolism. Am J Physiol 1997; 273: E903-E907
103. Cumin F, Baum HP, Levens N. Mechanism of leptin removal from the circulation by the kidney. J Endocrinol 1997; 155: 577-585
104. Lönnqvist F, Nordfors L, JanssonMet al. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 1997; 99: 2398-2404
105. Aminzadeh MA, Pahl MV, Barton CH et al. Human uraemic plasmastimulates release of leptin and uptake of tumour necrosis factor-alpha in visceral adipocytes. Nephrol Dial Transplant 2009; 24: 3626-3631
106. Kalbacher E, Koppe L, Zarrouki B et al. Human uremic plasma and not urea induces exuberant secretion of leptin in 3T3-L1 adipocytes. J Ren Nutr 2011; 21: 72-75
107. Boden G, Chen X, Mozzoli M et al. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996; 81: 3419-3423
108. Garibotto G, Russo R, Franceschini R et al. Inter-organ leptin exchange in humans. Biochem Biophys Res Commun 1998; 247: 504-509
109. Dagogo-Jack S, Ovalle F, Landt M. Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18: 34-40
110. Silva MI, Vale BS, Lemos CC et al. Body adiposity index assess body fat with high accuracy in nondialyzed chronic kidney disease patients. Obesity (Silver Spring) 2013; 21: 546-552
111. Ho KJ, Xue H, Mauro CR et al. Impact of uremia on human adipose tissue phenotype. J Surg Res 2013; 179: 175-182
112. Ruhl CE, Harris TB, Ding J et al. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. Am J Clin Nutr 2007; 85: 1121-1126
113. Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656
114. Obata Y, Yamada Y, Takahi Y et al. Relationship between serum adiponectin levels and age in healthy subjects and patients with type 2 diabetes. Clin Endocrinol (Oxf ) 2013; 79: 204-210
115. Tacke F, Wustefeld T, Horn R et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-673
116. Perri A, Vizza D, Lofaro D et al. Adiponectin is expressed and secreted by renal tubular epithelial cells. J Nephrol 2013; 26: 1049-1054
117. von Eynatten M, Liu D, Hock C et al. Urinary adiponectin excretion a novel marker for vascular damage in type 2 diabetes. Diabetes 2009; 58: 2093-2099
118. Bruun JM, Lihn AS, Verdich C et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-E533
119. Chedraui P, Perez-Lopez FR, Escobar GS et al. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas 2014; 79: 86-90
120. Nusken KD, Petrasch M, Rauh M et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant 2009; 24: 2832-2838
121. Kocelak P, Olszanecka-Glinianowicz M, Owczarek A et al. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects. Clin Chem Lab Med 2015; 53: 793-799
122. Spoto B, Mattace-Raso F, Sijbrands E et al. Resistin and allcause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrol Dial Transplant 2013; 28(Suppl 4): iv181-iv187
123. Fargnoli JL, Sun Q, OlenczukDet al. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010; 162: 281-288
124. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604
125. Malyszko J, Malyszko JS, Kozminski P et al. Elevated resistin is related to inflammation and residual renal function in haemodialysed patients. Nephrology (Carlton) 2007; 12: 246-253
126. Friedman JM. Leptin and the regulation of body weigh. Keio J Med 2011; 60: 1-9
127. Scholze A, Tepel M. Role of leptin in reverse epidemiology in chronic kidney disease. Semin Dial 2007; 20: 534-538
128. Liu Q, Yuan B, LoKA et al. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc Natl Acad Sci USA 2012; 109: 14568-14573
129. Qi Y, Takahashi N, Hileman SM et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529
130. Ekramzadeh M, Sohrabi Z, Salehi M et al. Adiponectin as a novel indicator of malnutrition and inflammation in hemodialysis patients. Iran J Kidney Dis 2013; 7: 304-308
131. Curat CA,Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747
132. Berndt J, Kloting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
133. Pagano C, Pilon C, Olivieri M et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 3165-3170
134. Varma V, Yao-Borengasser A, Rasouli N et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007; 92: 666-672
135. Chang YC, Chang TJ, Lee WJ et al. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissuewith inflammation, insulin resistance, and plasma lipids. Metabolism 2010; 59: 93-99
136. Wang P, van Greevenbroek MM, Bouwman FG et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007; 454: 971-976
137. Rajala MW, Qi Y, Patel HR et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679
138. Sato N, Kobayashi K, Inoguchi T et al. Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology 2005; 146: 273-279
139. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
140. Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metab J 2013; 37: 404-414
141. Loffreda S, Yang SQ, Lin HZ et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65
142. Lord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901
143. Zhao Y, Sun R, You L et al. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 2003; 300: 247-252
144. De Rosa V, Procaccini C, Cali G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007; 26: 241-255
145. Joffre O, Santolaria T, Calise D et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88-92
146. Umemoto Y, Tsuji K, Yang FC et al. Leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells. Blood 1997; 90: 3438-3443
147. Martinez-Anso E, Lostao MP, Martinez JA. Immunohistochemical localization of leptin in rat kidney. Kidney Int 1999; 55: 1129-1130
148. Elis Yildiz S, Deprem T, Karadag Sari E et al. Immunohistochemical distribution of leptin in kidney tissues of melatonin treated diabetic rats. Biotech Histochem 2015; 90: 270-277
149. Serradeil-Le Gal C, Raufaste D, Brossard G et al. Characterization and localization of leptin receptors in the rat kidney. FEBS Lett 1997; 404: 185-191
150. Be?towski J,Wjcicka G, Górny D et al. Human leptin administered intraperitoneally stimulates natriuresis and decreases renal medullary Na+, K+-ATPase activity in the rat-impaired effect in dietary-induced obesity. Med Sci Monit 2002; 8: BR221-BR229
151. Jackson EK, Li P. Human leptin has natriuretic activity in the rat. Am J Physiol 1997; 272: F333-F338
152. Vecchione C, Maffei A, Colella S et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002; 51: 168-173
153. Ortiz PA, Garvin JL. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Ren 2002; 282: F777-F784
154. Be?towski J, Jamroz-Wiśniewska A, Borkowska E et al. Upregulation of renal Na+, K+-ATPase: the possible novel mechanism of leptin-induced hypertension. Pol J Pharmacol 2004; 56: 213-222
155. Lee MP, Orlov D, Sweeney G. Leptin induces rat glomerular mesangial cell hypertrophy, but does not regulate hyperplasia or apoptosis. Int J Obes (Lond) 2005; 29: 1395-1401
156. Zeidan A, Purdham DM, Rajapurohitam V et al. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II-and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther 2005; 315: 1075-1084
157. Allison MA, Jenny NS, McClelland RL et al. The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis. J Hum Hypertens 2015; 29: 127-133
158. Lee MP, Madani S, Sekula D et al. Leptin increases expression and activity of matrix metalloproteinase-2 and does not alter collagen production in rat glomerular mesangial cells. Endocr Res 2005; 31: 27-37
159. Han DC, Isono M, Chen S et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001; 59: 1315-1323
160. Vu D, Tellez-Corrales E, Sakharkar P et al. Impact of NFkappaB gene polymorphism on allograft outcome in Hispanic renal transplant recipients. Transpl Immunol 2013; 28: 18-23
161. Fantuzzi G. Adiponectin in inflammatory and immunemediated diseases. Cytokine 2013; 64: 1-10
162. Scotece M, Conde J, Lopez Vet al. Adiponectin and leptin: new targets in inflammation. Basic Clin Pharmacol Toxicol 2014; 114: 97-102
163. Christou GA, Kiortsis DN. The role of adiponectin in renal physiology and development of albuminuria. J Endocrinol 2014; 221: R49-R61
164. Burnett MS, Lee CW, Kinnaird TD et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005; 182: 241-248
165. Adya R, Tan BK, Punn A et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365
166. Wang P, Xu TY, Guan YF et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81: 370-380
167. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758
168. Pirvulescu MM, Gan AM, Stan D et al. Subendothelial resistin enhances monocyte transmigration in a co-culture of human endothelial and smooth muscle cells by mechanisms involving fractalkine, MCP-1 and activation of TLR4 and Gi/o proteins signaling. Int J Biochem Cell Biol 2014; 50: 29-37
169. Li Y, Zhang Y, Dorweiler B et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 2008; 283: 34833-34843
170. Kim SR, Bae YH, Bae SK et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886-895
171. Maggio AB, Wacker J, Montecucco F et al. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr 2012; 161: 1022-1027
172. Romacho T, Azcutia V, Vazquez-Bella M et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455-2463
173. Calabro P, Samudio I, Willerson JT et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-3340
174. Huang Q, Guo Y, Zeng H et al. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr Res 2011; 36: 93-100
175. Song HK, Lee MH, Kim BK et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: F1485-F1494
176. Boini KM, Zhang C, Xia M et al. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta 2010; 1801: 1294-1304
177. Briffa JF, McAinch AJ, Poronnik P et al. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol 2013; 305: F1629-F1636
178. HamrickMW, Ferrari SL. Leptin and the sympathetic connection of fat to bone. Osteoporos Int 2008; 19: 905-912
179. Zhang J,Wang N. Leptin in chronic kidney disease: a link between hematopoiesis, bone metabolism, and nutrition. Int Urol Nephrol 2014; 46: 1169-1174
180. Tsuji K, Maeda T, Kawane T et al. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 2010; 25: 1711-1723
181. Gainsford T, Alexander WS. A role for leptin in hemopoieses? Mol Biotechnol 1999; 11: 149-158
182. Axelsson J, Qureshi AR,Heimburger Oet al. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis 2005; 46: 628-634
183. Nasri H. Association of serum leptin with anemia in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 2006; 17: 521-525
184. Stenvinkel P, Heimburger O, Lonnqvist F et al. Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure? Kidney Int 1998; 53: 1430-1431
185. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89
186. Tamura T, Furukawa Y, Taniguchi R et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 2007; 71: 623-630
187. Gnacinska M, Malgorzewicz S, Lysiak-Szydlowska W et al. The serum profile of adipokines in overweight patients with metabolic syndrome. Endokrynol Pol 2010; 61: 36-41
188. Sahin G, Akay OM, Uslu S et al. Association between endothelial and platelet function markers and adiponectin in renal transplanted recipients on cyclosporine and tacrolimus immunosuppression based therapy. Nephrology (Carlton) 2015; 20: 392-398
189. Malgorzewicz S, Debska-Slizien A, Czajka B et al. Adipokines and nutritional status in kidney transplant recipients. Transplant Proc 2014; 46: 2622-2626
190. Wang XH, Dou LZ, Gu C et al. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac J Trop Med 2014; 7: 55-62
191. Hung WC, Yu TH, Hsu CC et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clin Invest Med 2015; 38: E100-E109
192. Dahl TB, Yndestad A, Skjelland M et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980
193. Weikert C, Westphal S, Berger K et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008; 93: 2647-2653
194. Frankel DS, Vasan RS, D'Agostino RB Sr et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009; 53: 754-762
195. Pham PT, Pham PM, Pham SV et al. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 2011; 4: 175-186
196. Bayes B, Lauzurica R, Granada ML et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 2004; 78: 26-30
197. Romanowski M, Dziedziejko V, Maciejewska-Karlowska A et al. Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus. Pharmacogenomics 2015; 16: 1-9
198. Shu KH, Wu MJ, Chen CH et al. Serum adipokine levels in renal transplant recipients. Transplant Proc 2014; 46: 381-384
199. Olszanecka-Glinianowicz M, Owczarek A, Bozentowicz-Wikarek M et al. Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population-results from the PolSenior substudy. Metabolism 2014; 63: 1409-1418
200. Xiang RL, Mei M, Su YC et al. Visfatin protects rat pancreatic beta-cells against IFN-gamma-induced apoptosis through AMPK and ERK1/2 signaling pathways. Biomed Environ Sci 2015; 28: 169-177
201. Kim da S, Kang S, Moon NR et al. Central visfatin potentiates glucose-stimulated insulin secretion and beta-cell mass without increasing serum visfatin levels in diabetic rats. Cytokine 2014; 65: 159-166
202. Yano Y, Hoshide S, Ishikawa J et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens (Greenwich) 2007; 9: 775-782
203. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract 2009; 113: c16-c23
204. Prior SL,TangTS,GillGVet al. Adiponectin, total antioxidant status, and urine albumin excretion in the low-risk golden years type 1 diabetes mellitus cohort. Metabolism 2011; 60: 173-179
205. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913
206. Scheid MP, Sweeney G. The role of adiponectin signaling in metabolic syndrome and cancer. Rev Endocr Metab Disord 2014; 15: 157-167
207. Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab 2014; 28: 59-69
208. Scholze A, Rattensperger D, Zidek Wet al. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007; 15: 1617-1622
209. Moraes-Vieira PM, Bassi EJ, Larocca RA et al. Leptin deficiency modulates allograft survival by favoring a Th2 and a regulatory immune profile [corrected]. Am J Transplant 2013; 13: 36-44
210. Zoccali C, Postorino M, Marino C et al. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med 2011; 269: 172-181
211. Rhee CM, Nguyen DV, MoradiHet al. Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kidney Dis 2015; 66: 313-321
212. ChungW, Jung ES, Shin D et al. Lowresistin level is associated with poor hospitalization-free survival in hemodialysis patients. J Korean Med Sci 2012; 27: 377-381
213. Nagy K, Ujszaszi A, Czira ME et al. Association between serum resistin level and outcomes in kidney transplant recipients. Transpl Int 2016; 29: 352-361